FrancophonIA/ELRC3.0 huggingface dataset:
English: There is limited experience in patients with a history of seizure disorders, including alcohol withdrawal seizures.
Estonian: Krambiseisundite (sh alkoholi võõrutusega seotud krambihoogude) anamneesiga patsientidel on ravimi kasutamise kogemus vähene.
English: Blister: Clear PVC/PVdC-aluminium blisters in cardboard boxes Pack sizes of 7, 14, 28, 42, 49 and 98 film-coated tablets
Estonian: Blisterpakend: läbipaistvad PVC/PVdC-alumiinium blisterpakendid pappkarpides.
English: Myalgia
Estonian: Segasusseisund
English: This is repeated every 21 days for six courses or until the disease gets worse.
Estonian: Seda korratakse iga 21 päeva järel 6 kuuri või kuni haiguse süvenemiseni.
English: The European Commission granted a marketing authorisation valid throughout the EU for Topotecan Hospira on 10 June 2010.
Estonian: Euroopa Komisjon andis Topotecan Hospira müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10. juunil 2010.
English: The patient's blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels.
Estonian: Enne ravi tuleb kontrollida patsiendi vere leukotsüüdi-, trombotsüüdi- ja hemoglobiinisisaldust, et need ei oleks allpool kehtestatud miinimumväärtusi.
English: It is also used together with cisplatin (another anticancer medicine) to treat women with cervical cancer (cancer of the cervix), when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix).
Estonian: Topotecan Hospirat kasutatakse ka koos tsisplatiiniga (samuti vähiravim) emakakaelavähi raviks, kui vähk on pärast kiiritusravi taastunud või kui haigus on kaugelearenenud staadiumis (IVB staadium: vähk on levinud emakakaelast kaugemale).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Topotecan Hospira.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Topotecan Hospira topotecan
Estonian: Topotecan Hospira topotekaan
English: Treatment with Topotecan Hospira should only be given under the supervision of a doctor experienced in the use of chemotherapy.
Estonian: Ravi Topotecan Hospiraga peab toimuma üksnes keemiaravi kasutamises kogenud arsti järelevalve all.
English: For lung cancer, Topotecan Hospira is given every day for five days with a three-week interval between the start of each course.
Estonian: Kopsuvähi korral manustatakse Topotecan Hospirat iga päev 5 päeva jooksul, jättes ravikuuride alguse vahele 3nädalase intervalli.
English: This means that Topotecan Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU).
Estonian: See tähendab, et Topotecan Hospira on sarnane võrdlusravimiga, millel juba on Euroopa Liidus müügiluba.
English: Because Topotecan Hospira produces the same levels of the active substance in the body as the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Estonian: Et Topotecan Hospira tekitab organismis sama toimetaine sisalduse kui võrdlusravim, peetakse selle kasulikkust ja riske samadeks mis võrdlusravimil.
English: This document is a summary of the European Public Assessment Report (EPAR) for Topotecan Hospira.
Estonian: Käesolev dokument on ravimi Topotecan Hospira Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP concluded that, in accordance with EU requirements, Topotecan Hospira has been shown to be comparable to Hycamtin.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Topotecan Hospira võrdvääärsus ravimiga Hycamtin.
English: No additional studies were needed as Topotecan Hospira is given by infusion and contains the same active substance as the reference medicine, Hycamtin.
Estonian: Patsientide lisauuringuid ei olnud vaja, sest Topotecan Hospirat manustatakse infusioonina ja ravim sisaldab sama toimeainet kui võrdlusravim Hycamtin.
English: The Committee recommended that Topotecan Hospira be given marketing authorisation.
Estonian: Komitee soovitas anda Topotecan Hospira müügiloa.
English: Topotecan Hospira also affects non-cancer cells, which causes side effects.
Estonian: Topotecan Hospira mõjutab ka muid rakke peale vähirakkude ning see põhjustab kõrvalnähte.
English: When used with cisplatin in cervical cancer, Topotecan Hospira is given on days 1, 2 and 3 (with cisplatin given on day 1).
Estonian: Koos tsisplatiiniga emakakaelavähi raviks kasutamisel manustatakse Topotecan Hospirat infusioonina 1., 2. ja 3. päeval (manustades tsisplatiini 1. päeval).
English: Topotecan Hospira is a concentrate that is made up into a solution for infusion (drip into a vein).
Estonian: Topotecan Hospira on kontsentraat, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: The full EPAR for Topotecan Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Topotecan Hospira kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Kui vajate Topotecan Hospira toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The dose of Topotecan Hospira to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Estonian: Topotecan Hospira annus sõltub ravitavast vähiliigist ning patsiendi kaalust ja pikkusest.
English: The active substance in Topotecan Hospira, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Estonian: Topotecan Hospira toimeaine topotekaan on topoisomeraasiinhibiitorite rühma kuuluv vähiravim.
English: Therefore, the CHMP's view was that, as for Hycamtin, the benefit outweighs the identified risk.
Estonian: Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini korral, ületab Topotecan Hospira kasulikkus sellega kaasnevad riskid.
English: Topotecan Hospira is a ‘hybrid medicine'.
Estonian: Topotecan Hospira on hübriidravim.
English: Other information about Topotecan Hospira:
Estonian: Muu teave Topotecan Hospira kohta
English: The reference medicine Hycamtin is available as a powder to be made up into a solution for infusion and not as a concentrate.
Estonian: Võrdlusravimit Hycamtini turustatakse mitte kontsentraadina, vaid pulbrina, millest valmistatakse infusioonilahus.
English: For full details, see the Summary of Product Characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: Why has Topotecan Hospira been approved?
Estonian: Miks Topotecan Hospira heaks kiideti?
English: What is Topotecan Hospira?
Estonian: Mis on Topotecan Hospira?
English: The doses may need to be adjusted or other medicines given to the patients, when the level of white blood cells remains particularly low.
Estonian: Kui leukotsüütide sisaldus püsib eriti väike, võib olla vaja annuseid kohandada või anda patsientidele muid ravimeid.
English: What are the benefit and risk of Topotecan Hospira?
Estonian: Milles seisneb Topotecan Hospira kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Topotecan Hospira used?
Estonian: Kuidas Topotecan Hospirat kasutatakse?
English: What is Topotecan Hospira used for?
Estonian: Milleks Topotecan Hospirat kasutatakse?
English: How does Topotecan Hospira work?
Estonian: Kuidas Topotecan Hospira toimib?
English: How has Topotecan Hospira been studied?
Estonian: Kuidas Topotecan Hospirat uuriti?
English: What measures are being taken to ensure the safe and effective use of Kanjinti?
Estonian: Mis meetmed võetakse, et tagada Kanjinti ohutu ja efektiivne kasutamine?
English: Further information on Kanjinti can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Kanjinti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Patients who do not have significant reactions to the first 90-minute infusion can receive subsequent infusions over 30 minutes.
Estonian: Patsiendid, kellel ei esine esimese 90-minutilise infusiooni ajal olulisi reaktsioone, võivad saada järgmised infusioonid 30-minutistena.
English: Kanjinti (trastuzumab)
Estonian: Kanjinti (trastusumaab)
English: This means that Kanjinti is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Estonian: See tähendab, et Kanjinti on väga sarnane teise bioloogilise ravimiga (võrdlusravimiga), millel juba on ELis müügiluba.
English: What is Kanjinti and what is it used for?
Estonian: Mis on Kanjinti ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Kanjinti are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Kanjinti kasutamise kohta pidevat järelevalvet.
English: In the light of all the data provided the difference was not assessed to be relevant and it was concluded that Kanjinti would behave in the same way as Herceptin in its approved indications.
Estonian: Kõigi esitatud andmete põhjal ei peetud seda erinevust asjakohaseks ja järeldati, et Kanjinti toimib Herceptini heakskiidetud näidustustel samamoodi kui Herceptin.
English: Therefore, the Agency's view was that, as for Herceptin, the benefit of Kanjinti outweighs the identified risk and it can be authorised.
Estonian: Seetõttu on amet arvamusel, et nagu ka Herceptini korral, ületab Kanjinti kasulikkus sellega kaasnevad riskid ja seda võib kasutada.
English: Kanjinti is a cancer medicine used to treat the following conditions:
Estonian: Kanjinti on vähiravim, mida kasutatakse järgmiste seisundite raviks:
English: Side effects reported with Kanjinti are carefully evaluated and any necessary action taken to protect patients.
Estonian: Kanjinti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: What are the risks associated with Kanjinti?
Estonian: Mis riskid Kanjintiga kaasnevad?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kanjinti have been included in the summary of product characteristics and the package leaflet.
Estonian: Kanjinti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Other information about Kanjinti
Estonian: Muu teave Kanjinti kohta
English: Kanjinti can only be obtained with a prescription and treatment should be started by a doctor who has experience in the use of cancer medicines.
Estonian: Kanjinti on retseptiravim ja ravi peab alustama vähiravimite kasutamises kogenud arst.
English: • metastatic breast cancer (cancer that has spread to other parts of the body).
Estonian: • Metastaatiline rinnavähk (vähk on levinud organismis ka mujale).
English: Kanjinti can cause cardiotoxicity (harm to the heart), including heart failure (when the heart does not work as well as it should).
Estonian: Kanjinti võib põhjustada kardiotoksilisust (kahjustada südant), sealhulgas südamepuudulikkust.
English: In addition, one study involving 696 patients with early breast cancer that overexpressed HER2 showed that Kanjinti was effective in treating the condition.
Estonian: Peale selle tõendati ühes uuringus, milles osales 549 HER2 üleekspressiooniga varases staadiumis rinnavähiga patsienti, et Kanjinti oli seisundi ravis efektiivne.
English: The most common or serious side effects with Kanjinti are heart problems, reactions related to the Kanjinti infusion, reduced levels of blood cells (especially white blood cells), infections and lung problems.
Estonian: Kanjinti kõige sagedamad või raskemad kõrvalnähud on südamehäired, Kanjinti infusiooniga seotud reaktsioonid, vererakkude, eriti leukotsüütide (vere valgeliblede) sisalduse vähenemine, infektsioonid (nakkused) ja kopsuhäired.
English: The dose depends on the patient's body weight, on the condition being treated and on whether Kanjinti is given every week or every 3 weeks.
Estonian: Annus sõltub patsiendi kehamassist, ravitavast seisundist ja sellest, kas Kanjintit manustatakse iga nädal või iga 3 nädala järel.
English: Because Kanjinti is a biosimilar medicine, the studies on effectiveness and safety of trastuzumab carried out with Herceptin do not all need to be repeated for Kanjinti.
Estonian: Et Kanjinti on bioloogiliselt sarnane ravim, ei pea Herceptiniga tehtud trastusumaabi efektiivsus- ja ohutusuuringuid Kanjintiga kordama.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Kanjinti has been shown overall to have a comparable quality, safety and effectiveness to Herceptin.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Kanjinti võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil Herceptini profiiliga.
English: Studies have also shown that giving Kanjinti produces similar levels of the active substance in the body to giving Herceptin.
Estonian: Uuringud on samuti tõendanud, et Kanjinti tekitab organismis sarnase toimeainesisalduse kui Herceptin.
English: For more information about using Kanjinti, see the package leaflet or contact a doctor or pharmacist.
Estonian: Lisateavet Kanjinti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: After treatment of up to a year, 48% of those given Kanjinti (172 of 358) and 41% of those given the reference medicine Herceptin (137 of 338) had no invasive cancer cells in the breasts or surrounding lymph nodes.
Estonian: Kuni aastase ravi järel oli patsiente, kellel puudusid rinnanäärmes või ümbritsevates lümfisõlmedes invasiivsed vähirakud, Kanjinti uuringurühmas 48% (172 patsienti 358st) ja võrdlusravimi Herceptini rühmas 41% (137 patsienti 338st).
English: It is also used in combination with other cancer medicines: with paclitaxel or docetaxel, or with another class of medicines called aromatase inhibitors;
Estonian: Seda kasutatakse ka koos teiste vähiravimitega - koos paklitakseeli või dotsetakseeliga või teatud muu klassi ravimitega (aromataasi inhibiitoritega).
English: For cancers that are locally advanced (including those that are inflammatory) or more than 2 cm wide, Kanjinti is used before surgery in combination with chemotherapy and then again after surgery on its own;
Estonian: Lokaalselt levinud (ka põletikuliste) või üle 2 cm suuruste kasvajate korral kasutatakse Kanjintit enne operatsiooni koos keemiaraviga ja seejärel uuesti pärast operatsiooni ainuravimina.
English: The reference medicine for Kanjinti is Herceptin.
Estonian: Kanjinti võrdlusravim on Herceptin.
English: Kanjinti must not be used in people who are hypersensitive (allergic) to trastuzumab, mouse proteins or to any of the other ingredients.
Estonian: Kanjintit ei tohi kasutada patsiendid, kes on trastusumaabi, hiirevalkude või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: How is Kanjinti used?
Estonian: Kuidas Kanjintit kasutatakse?
English: • metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or fluorouracil (other cancer medicines).
Estonian: • Metastaatiline maovähk - Kanjintit kasutatakse koos tsisplatiini ja kas kapetsitabiini või fluorouratsiiliga (samuti vähiravimid).
English: • early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable.
Estonian: • Varases staadiumis rinnavähk (vähk esineb rinnanäärmes või kaenlalümfisõlmedes, kuid ei ole levinud organismis mujale) pärast operatsiooni, keemiaravi (vähi ravimravi) või kiiritusravi, kui asjakohane.
English: Kanjinti can only be used when the cancer ‘overexpresses HER2': this means that the cancer produces a protein called HER2 in large quantities on the cancer cells.
Estonian: Kanjintit tohib kasutada üksnes HER2 üleekspressiooniga vähi korral (kui kasvajarakkude pinnal tekib palju valku HER2).
English: It can also be used earlier in treatment, in combination with chemotherapy.
Estonian: Kanjintit tohib kasutada ka ravis varem koos keemiaraviga.
English: Laboratory studies comparing Kanjinti with Herceptin have shown that the active substance in Kanjinti is highly similar to that in Herceptin in terms of structure, purity and biological activity.
Estonian: Kanjintit võrreldi Herceptiniga laboriuuringutes, mis tõendasid, et Kanjinti toimeaine sarnaneb struktuuri, puhtuse ja bioloogilise toime poolest Herceptini toimeainega.
English: An overview of Kanjinti and why it is authorised in the EU
Estonian: Ülevaade ravimist Kanjinti ja ELis müügiloa väljastamise põhjendus
English: How does Kanjinti work?
Estonian: Kuidas Kanjinti toimib?
English: What benefits of Kanjinti have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kanjinti kasulikkus?
English: The active substance in Kanjinti, trastuzumab, is a monoclonal antibody (a type of protein) designed to recognise and attach to the HER2 protein.
Estonian: Kanjinti toimeaine trastusumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära valgu HER2 ja seondub sellega.
English: Kanjinti is a ‘biosimilar medicine'.
Estonian: Kanjinti on bioloogiliselt sarnane ravim.
English: It is used on its own when other treatments have not worked or are not suitable.
Estonian: Kui muu ravi ei ole toiminud või ei sobi, kasutatakse Kanjintit ainuravimina.
English: Kanjinti contains the active substance trastuzumab.
Estonian: Kanjinti toimeaine on trastusumaab.
English: Why is Kanjinti authorised in the EU?
Estonian: ELis Kanjintile väljastatud müügiloa põhjendus
English: These precautions are also applicable to children.
Estonian: Need ettevaatusabinõud kehtivad ka lastele.
English: Insufficient evidence
Estonian: Ebapiisav tõendusmaterjal
English: Frequency not known (cannot be estimated from available data)
Estonian: Sagedus teadmata (ei saa hinnata olemasolevate andmete alusel)
English: >R (Resistant)
Estonian: >R (resistentne)
English: Total parenteral nutrition:
Estonian: Täielik parenteraalne toitmine:
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: {27 May 2015}
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: {27 mai 2015 }
English: Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:
Estonian: Muud olulised kõrvaltoimed, mille sagedus on teadmata, kuid millest tuleks kohe arstile teatada:
English: However, some may be serious and need medical attention.
Estonian: Mõned kõrvaltoimed võivad siiski olla tõsised ja vajada arstiabi.
English: Osmolality: 500± 50 mOsm/kg
Estonian: Osmolaalsus: 500 ± 50 mOsm/kg
English: Difference in proportions and the 95% confidence interval (CI)
Estonian: Osakaalude erinevus ja 95% usaldusvahemik (CI)
English: Prophylaxis should be initiated on the day of transplant and may be administered for up to 100 days.
Estonian: Profülaktikat tuleks alustada siirdamise päeval ning ravimit võib manustada kuni 100 päeva.
English: In this analysis a successful response was seen in 41 % of patients in both treatment arms.
Estonian: Selles analüüsis esines edukas vastus 41% patsientidest mõlemas rühmas.
English: Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.
Estonian: Antud hetkel teadaolevad andmed on esitatud lõikudes 4.8 ja 5.1, aga soovitusi annustamise kohta ei ole võimalik anda.
English: • A disorder in which the body's immune system attacks part of the peripheral nervous system
Estonian: • Häire, mille puhul organismi immuunsüsteem ründab perifeerse närvisüsteemi teatud osa
English: • You have had an allergic reaction to other azoles.
Estonian: • kui teil on esinenud allergilisi reaktsioone teiste asoolide suhtes.
English: Treatment duration should be as short as possible depending on the patient's clinical and mycological response.
Estonian: Ravi kestus peaks olema võimalikult lühike, sõltuvalt patsiendi kliinilisest ja mükoloogilisest ravivastusest.
English: These results are relevant to other populations and routes of administration.
Estonian: Need tulemused kehtivad ka teiste populatsioonide ja manustamisteede korral.
English: Candida Species
Estonian: Candida liigid
English: • Problems with balance or coordination
Estonian: • Tasakaalu- ja koordinatsioonihäired
English: Dosage adjustment (Adults)
Estonian: Annuse kohandamine (täiskasvanud)
English: The following instructions apply to both Treatment and Prophylaxis.
Estonian: Järgnevad juhendid kehtivad mõlemale - ravile ja profülaktikale.
English: Other Candida spp.4
Estonian: Teised Candida spp.4
English: The recommended dose for adults (including elderly patients) is as follows:
Estonian: Soovitatav annus täiskasvanutele (kaasa arvatud eakad patsiendid) on järgmine:
English: Patients less than 40 kg**
Estonian: Patsiendid kehakaaluga alla 40 kg**
English: Maximum increase in prothrombin time was approximately 2-fold
Estonian: Protrombiiniaja maksimaalne pikenemine oli ligikaudu kahekordne
English: However, this reduced response was not correlated with elevated MICs.
Estonian: Vähenenud vastus ei korreleerunud siiski suurenenud MIC väärtustega.
English: Patients with a weakened immune system or those with difficult infections may require long term treatment to prevent the infection from returning.
Estonian: Nõrgenenud immuunsüsteemiga või raskete infektsioonidega patsientidel võib osutuda vajalikuks pikaajaline ravi, et vältida infektsiooni taastumist.
English: Clinical Experience Successful outcome in this section is defined as complete or partial response.
Estonian: Kliiniline kogemus Käesolevas lõigus on kliiniline efektiivsus defineeritud kui täielik või osaline reageerimine ravile.
English: pH of the reconstituted solution is 4.0 to 7.0.
Estonian: Manustamiskõlbliku lahuse pH on 4,0 kuni 7,0.
English: The median duration of study drug prophylaxis was 95.5 days in the MITT group.
Estonian: Uuringuravimi profülaktika mediaankestus oli MITT rühmas 95,5 päeva.
English: *Oral dosage forms of voriconazole are available from other manufacturers **This also applies to patients aged 15 years and older.
Estonian: * Saadaval on vorikonasooli suukaudsed ravimvormid teiste tootjate poolt ** See kehtib ka 15-aastaste ja vanemate patsientide kohta.
English: The Investigator's assessment of successful outcome at each of these time points is shown in the following table.
Estonian: Uurijate eduka vastuse hinang igal neist ajahetkedest on toodud järgnevas tabelis.
English: No clinically significant differences were seen when the safety data were analysed by age, race, or gender.
Estonian: Kliiniliselt olulisi erinevusi ei esinenud andmete analüüsimisel vanuse, rassi või soo alusel.
English: The survival rate at Day 180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).
Estonian: Elulemusmäär 180. päeval oli 80,0% (32/40) ja 1. aastal 70,0% (28/40).
English: Interaction Geometric mean changes (%)
Estonian: Koostoime Geomeetrilise keskmise muutus (%)
English: The median treatment duration was 15 days in both treatment arms.
Estonian: Keskmine ravi kestus oli mõlemas ravirühmas 15 päeva.
English: Frequency categories are expressed as: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (cannot be estimated from the available data).
Estonian: Esinemissagedused on määratletud järgmiselt: väga sage (≥1/10), sage (≥1/100 kuni <1/10), aeg-ajalt (≥1/1000 kuni <1/100), harv (≥1/10 000 kuni <1/1000), väga harv (<1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).